Search

Your search keyword '"Martin Glas"' showing total 327 results

Search Constraints

Start Over You searched for: Author "Martin Glas" Remove constraint Author: "Martin Glas"
327 results on '"Martin Glas"'

Search Results

151. RTHP-25. TTFIELDS DOSE DISTRIBUTION ALTERS TUMOR GROWTH PATTERNS: AN IMAGING-BASED ANALYSIS OF THE RANDOMIZED PHASE 3 EF-14 TRIAL

152. ACTR-31. THE USE OF TTFIELDS FOR NEWLY DIAGNOSED GBM PATIENTS IN GERMANY IN ROUTINE CLINICAL CARE (TIGER: TTFIELDS IN GERMANY IN ROUTINE CLINICAL CARE)

153. Non-invasive tumor decoding and phenotyping of cerebral gliomas utilizing multiparametric

154. To resect or not to resect? Risks and benefits of surgery in older patients with glioblastoma

155. Health-related quality of life and neurocognitive functioning with lomustine-temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial

156. Comparison of L-Methyl-11C-Methionine PET With Magnetic Resonance Spectroscopy in Detecting Newly Diagnosed Glioma

158. Targeting the Post-Irradiation Tumor Microenvironment in Glioblastoma via Inhibition of CXCL12

159. Primäre ZNS-Lymphome

160. Baseline T1 hyperintense and diffusion-restricted lesions are not linked to prolonged survival in bevacizumab-treated glioblastoma patients of the GLARIUS trial

161. Tumoren der Hirnnerven

162. Intraoperative Radiotherapy in Newly Diagnosed Glioblastoma (INTRAGO) : an Open-Label, Dose-Escalation Phase I/II Trial

163. P14.66 TTFields dose distribution and tumor growth patterns confirm clinical activity of TTFields : MRI analysis of the randomized phase 3 EF-14 trial

164. Tumoren der Sellaregion

165. Blood-Based Biomarkers in High Grade Gliomas : a Systematic Review

166. Regorafenib in patients with recurrent high-grade astrocytoma

167. Tumoren der Pinealisregion

168. Gliome

169. Neuronale und neurogliale Tumoren

170. Analysis of the EF-14 phase III trial reveals that tumor treating fields alter progression patterns in glioblastoma

171. Hybrid 11C-MET PET/MRI Combined With 'Machine Learning' in Glioma Diagnosis According to the Revised Glioma WHO Classification 2016

172. Wer ist ... Martin Glas?

173. Correction to: Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high‑grade glioma in clinical practice

174. A Science Friction Story: Molecular Interactions in Semiflexible Polymer Networks

175. Quantitative T1-mapping detects cloudy-enhancing tumor compartments predicting outcome of patients with glioblastoma

176. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab

177. Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial

178. 18F-fluoroethyl-L-tyrosine positron emission tomography for the differential diagnosis of tumefactive multiple sclerosis versus glioma: A case report

179. CTNI-79. PRICOTTF TRIAL: A PHASE I/II TRIAL OF TTFIELDS PRIOR AND CONCOMITANT TO RADIOTHERAPY IN NEWLY DIAGNOSED GLIOBLASTOMA

180. Evidence that Recurrence Patterns of TTFields Treated Patients Affect Patient Outcome: Post-Hoc Analysis of the Randomized Phase 3 EF-14 Trial

181. COVD-17. TUMOR TREATING FIELDS FOR GLIOBLASTOMA THERAPY DURING THE COVID-19 PANDEMIC: EXPERT CONSENSUS ON USE AND EXPERIENCE

183. Analysis of Serum miRNA in Glioblastoma Patients: CD44-Based Enrichment of Extracellular Vesicles Enhances Specificity for the Prognostic Signature

184. Abstract CT106: PriCoTTF trial: A phase I/II trial of TTFields prior and concomitant to radiotherapy in newly diagnosed glioblastoma

186. Xenografting for disease modeling of intramedullary spinal cord tumors: a systematic review

187. QOLP-20. QUALITY OF LIFE IN THE PHASE III CeTeG/NOA-09 TRIAL RANDOMIZING CCNU/TEMOZOLOMIDE (TMZ) COMBINATION THERAPY VS. STANDARD TMZ THERAPY FOR NEWLY DIAGNOSED MGMT-METHYLATED GLIOBLASTOMA

188. CBMT-17. NOVEL APPROACH OF UTILISING SERUM/PLASMA EV AND CELL-FREE RNA FOR TREATMENT MONITORING IN GLIOBLASTOMA PATIENTS

189. INNV-03. SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS USE IN THE EMEA REGION A REAL-WORLD DATA ANALYSIS

190. INNV-23. SAFETY AND ADVERSE EVENT PROFILE OF TUMOR TREATING FIELDS IN ELDERLY PATIENTS A POST-MARKET SURVEILLANCE ANALYSIS

191. Quality of life in the GLARIUS trial randomizing bevacizumab/irinotecan versus temozolomide in newly diagnosed, MGMT-nonmethylated glioblastoma

192. Use of FET PET in glioblastoma patients undergoing neurooncological treatment including tumour-treating fields : initial experience

193. NIMG-32. COMPARISON OF L-METHYL-11C-METHIONINE POSITRON EMISSION TOMOGRAPHY WITH MAGNETIC RESONANCE SPECTROSCOPY IN DETECTING NEWLY DIAGNOSED GLIOMA

194. Recurrent pseudoprogression in isocitrate dehydrogenase 1 mutant glioblastoma

195. 11C-MET PET/MRI for detection of recurrent glioma

196. ACTR-53. MGMT PROMOTER METHYLATION ANALYSIS FOR ALLOCATING COMBINED CCNU/TMZ CHEMOTHERAPY: LESSONS LEARNED FROM THE CeTeG/NOA-09 TRIAL

197. RARE-39. COMBINATION OF TUMOR TREATING FIELDS (TTFIELDS) WITH LOMUSTINE (CCNU) AND TEMOZOLOMIDE (TMZ) IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PATIENTS - A BI-CENTRIC ANALYSIS

199. P14.62 Safety and adverse event profile post-market surveillance analysis of Tumor Treating Fields (TTFields) in EMEA

Catalog

Books, media, physical & digital resources